Citigroup Increases GSK (LON:GSK) Price Target to GBX 2,250

GSK (LON:GSK) had its target price increased by research analysts at Citigroup from GBX 1,900 to GBX 2,250 in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s target price points to a potential upside of 3.78% from the stock’s current price.

Several other research firms also recently commented on GSK. Berenberg Bank raised their price objective on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research note on Monday, November 24th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a report on Thursday, January 15th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Finally, UBS Group reissued a “neutral” rating and issued a GBX 1,940 price objective on shares of GSK in a research note on Friday, January 23rd. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of GBX 1,917.86.

GSK Trading Up 0.4%

Shares of GSK stock opened at GBX 2,168 on Monday. GSK has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 2,219. The company’s fifty day simple moving average is GBX 1,861.08 and its 200-day simple moving average is GBX 1,682.05. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The stock has a market capitalization of £87.47 billion, a PE ratio of 16.30, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, equities analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Jonathan Symonds acquired 2,500 shares of the company’s stock in a transaction on Thursday, February 5th. The stock was acquired at an average price of GBX 2,114 per share, with a total value of £52,850. Also, insider Wendy Becker acquired 441 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were purchased at an average price of GBX 1,809 per share, with a total value of £7,977.69. In the last 90 days, insiders have purchased 4,591 shares of company stock valued at $9,069,269. 0.20% of the stock is owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.